![]() Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. You can access the replay dial-in information on the "Investors" section of Envista's website under the subheading "Events & Presentations." Presentation materials relating to Envista's results have been posted to the "Investors" section of Envista's website under the subheading "Quarterly Earnings." In addition, selected unaudited historical financial information for continuing operations has been posted to the "Investors" section of Envista's website.Įnvista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, Kerr, and KaVo united by a shared purpose: to partner with professionals to improve lives. A replay of the conference call will be available shortly after the conclusion of the call. PT start and referencing conference ID #7516382. The conference call can be accessed by dialing 87 within the U.S. The call and an accompanying slide presentation will be webcast on the "Investors" section of Envista's website, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Envista's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. We are raising our financial guidance for continuing operations for the year as follows:Įnvista will discuss its quarterly results and provide an outlook for 2021 during an investor conference call today starting at 2:00 P.M. We remain committed to our purpose of partnering with professionals to improve patients' lives and will continue to work to personalize, digitize, and democratize dental care." Since our IPO in September 2019, we have made significant progress in transforming our business from a broad mix of dental products to a focused company providing highly differentiated consumables and specialty dental products underpinned by strong digital workflow solutions. Aghdaei continued, "We are very pleased with our third quarter results and remain optimistic about the future of the dental industry. ![]() Our adjusted EBITDA margin was 19.6% reflecting the underlying profitability of our business and our focus on continuous improvement." Adjusted EBITDA for the third quarter was $119.1 million compared to $111.4 million for the third quarter of 2020.Īmir Aghdaei, Chief Executive Officer, remarked, "We grew significantly above pre-pandemic levels and delivered double-digit core growth over 2020 as we continued to benefit from the reshaping of our portfolio and our long-term investments in both commercial execution and innovation. Adjusted earnings per diluted share was $0.45 vs. Adjusted net income was $79.4 million, representing a 22% increase year over year. ![]() All commentary in this release relates to continuing operations unless otherwise noted.įor the quarter ended October 1, 2021, sales increased 11% to $607.3 million with core sales growth of 10.2% over the third quarter 2020.įor the third quarter, net income was $80.2 million or $0.45 per diluted share. For the current quarter the results of the Divestiture are reflected as discontinued operations in our financial statements as required by generally accepted accounting principles. We expect this transaction to close by the end of the year. 3, 2021 /PRNewswire/ - Envista Holdings Corporation (NYSE: NVST) today announced results for the third quarter 2021.Īs previously disclosed, in September we reached an agreement to sell our KaVo Treatment Unit and Instrument business (the "Divestiture").
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |